शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

REMUSNSEREMUS PHARMACEUTICALS LHighNeutral
Announced Tue, 3 Nov, 2026 · 15:58 IST

Consolidated H1 FY27 revenue Rs 614.12 crore; Rs 1 interim dividend

Revenue growth above 20%EBITDA margin compressionResults View source PDFExplain this filing

REMUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-3.4%Reaction day
₹844.20
prior close
₹840.05
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+2.2%-5.6% vs market

On the reaction day the stock moved 5.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
-0.0
15m
-0.0
30m
-0.0
Sessions after the filingfrom the prior close
StockMarketvs market
Reaction day
-3.4+2.2-5.6
Next day
-0.5+3.3-3.8
2d
-3.6pendingpending
3d
———
4d
———
5d
———
1w
———
15d
———
1m
———
2m
———
3m
———
UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated H1 FY27 revenue was Rs 614.12 crore against Rs 400.20 crore in H1 FY26; profit after tax was Rs 24.66 crore against Rs 21.59 crore. Operating profit before interest, tax, depreciation and other income was Rs 29.93 crore against Rs 26.91 crore. No quarterly figures were provided. Operating cash flow was positive at Rs 7.56 crore. The board approved a Rs 1 interim dividend, with November 7, 2026 as the record date.

Likely market impact

H1 sales growth and the Rs 1 interim dividend support sentiment, but slower profit growth and new subsidiary costs limit the benefit.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹614.1 Cr₹400.2 Cr+53.5%
Operating profit₹27.63 Cr₹24.97 Cr+10.7%
Profit after tax₹24.66 Cr₹21.59 Cr+14.2%
EBITDA margin4.9%6.7%−1.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.